Substance / Medication

Digitoxin

Overview

Active Ingredient
digitoxin
RxNorm CUI
3403

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

16 trials linked to this intervention

16
Total Trials
5
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
Batra Gorav, Aktaa Suleman, Camm A John et al. · Eur Heart J Qual Care Clin Outcomes · 2023
PMID: 36243903Meta-AnalysisFull text (PMC)
Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review.
Niforatos Joshua D, Ehmann Michael R, Balhara Kamna S et al. · Acad Emerg Med · 2023
PMID: 36326565Meta-Analysis
Arrhythmias Beyond Atrial Fibrillation Detection Using Smartwatches: A Systematic Review.
Pay Levent, Yumurtaş Ahmet Çağdaş, Satti Danish Iltaf et al. · Anatol J Cardiol · 2023
PMID: 36856589Meta-AnalysisFull text (PMC)
Safety and Effectiveness of Adjunctive Posterior Wall Isolation in Atrial Fibrillation Patients: An Updated Meta-Analysis.
Singh Sahib, Goel Swecha, Chaudhary Rahul et al. · Am J Cardiol · 2023
PMID: 37481814Meta-AnalysisFull text (PMC)
Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial.
Bavendiek Udo, Großhennig Anika, Schwab Johannes et al. · Clin Res Cardiol · 2023
PMID: 37087503RCTFull text (PMC)
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.
Bavendiek Udo, Großhennig Anika, Schwab Johannes et al. · N Engl J Med · 2025
PMID: 40879434Trial
Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Zeitlin Pamela L, Diener-West Marie, Callahan Karen A et al. · Ann Am Thorac Soc · 2017
PMID: 28006108TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Digitoxin (substance)
SNOMED CT
373534001
UMLS CUI
C0012258
RxNorm CUI
3403

Clinical Data

This intervention maps to 21 entities in the Ltrl knowledge graph.

6
Conditions
7
Biomarkers
4
Specialists
0
Symptoms
16
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.